JP2005531505A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005531505A5 JP2005531505A5 JP2003571402A JP2003571402A JP2005531505A5 JP 2005531505 A5 JP2005531505 A5 JP 2005531505A5 JP 2003571402 A JP2003571402 A JP 2003571402A JP 2003571402 A JP2003571402 A JP 2003571402A JP 2005531505 A5 JP2005531505 A5 JP 2005531505A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- protein
- follistatin
- disorder
- modification
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 52
- 102000004169 proteins and genes Human genes 0.000 claims 31
- 108090000623 proteins and genes Proteins 0.000 claims 31
- 102100020921 Follistatin Human genes 0.000 claims 18
- 108010014612 Follistatin Proteins 0.000 claims 18
- 230000004048 modification Effects 0.000 claims 15
- 238000012986 modification Methods 0.000 claims 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 208000035475 disorder Diseases 0.000 claims 9
- 201000006938 muscular dystrophy Diseases 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 101150079978 AGRN gene Proteins 0.000 claims 4
- 102100040026 Agrin Human genes 0.000 claims 4
- 108700019743 Agrin Proteins 0.000 claims 4
- 102000009027 Albumins Human genes 0.000 claims 4
- 108010088751 Albumins Proteins 0.000 claims 4
- 108010012820 Follistatin-Related Proteins Proteins 0.000 claims 4
- 102100029378 Follistatin-related protein 1 Human genes 0.000 claims 4
- 102100029379 Follistatin-related protein 3 Human genes 0.000 claims 4
- 101001062535 Homo sapiens Follistatin-related protein 1 Proteins 0.000 claims 4
- 101001021404 Homo sapiens G-protein coupled receptor-associated sorting protein 2 Proteins 0.000 claims 4
- 101000840577 Homo sapiens Insulin-like growth factor-binding protein 7 Proteins 0.000 claims 4
- 101000588007 Homo sapiens SPARC-like protein 1 Proteins 0.000 claims 4
- 101000864743 Homo sapiens Secreted frizzled-related protein 1 Proteins 0.000 claims 4
- 102100029228 Insulin-like growth factor-binding protein 7 Human genes 0.000 claims 4
- 108010077077 Osteonectin Proteins 0.000 claims 4
- 102100037599 SPARC Human genes 0.000 claims 4
- 102100031581 SPARC-like protein 1 Human genes 0.000 claims 4
- 101000862376 Synechocystis sp. (strain PCC 6803 / Kazusa) Fluorescence recovery protein Proteins 0.000 claims 4
- 102100020722 WAP, Kazal, immunoglobulin, Kunitz and NTR domain-containing protein 1 Human genes 0.000 claims 4
- 210000003205 muscle Anatomy 0.000 claims 4
- 208000021642 Muscular disease Diseases 0.000 claims 3
- 102000004472 Myostatin Human genes 0.000 claims 3
- 108010056852 Myostatin Proteins 0.000 claims 3
- 230000000087 stabilizing effect Effects 0.000 claims 3
- 238000009007 Diagnostic Kit Methods 0.000 claims 2
- 206010028289 Muscle atrophy Diseases 0.000 claims 2
- 208000010316 Myotonia congenita Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 125000000837 carbohydrate group Chemical group 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 230000013595 glycosylation Effects 0.000 claims 2
- 238000006206 glycosylation reaction Methods 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 201000000585 muscular atrophy Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 230000006320 pegylation Effects 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 206010003694 Atrophy Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 208000037141 Congenital muscular dystrophy, Fukuyama type Diseases 0.000 claims 1
- 208000029323 Congenital myotonia Diseases 0.000 claims 1
- 208000035810 Denervation atrophy Diseases 0.000 claims 1
- 208000001441 Familial Periodic Paralyses Diseases 0.000 claims 1
- 201000006813 Fukuyama congenital muscular dystrophy Diseases 0.000 claims 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010028372 Muscular weakness Diseases 0.000 claims 1
- 206010028424 Myasthenic syndrome Diseases 0.000 claims 1
- 206010028629 Myoglobinuria Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000026062 Tissue disease Diseases 0.000 claims 1
- 201000006793 Walker-Warburg syndrome Diseases 0.000 claims 1
- 210000000577 adipose tissue Anatomy 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 230000009693 chronic damage Effects 0.000 claims 1
- 201000011474 congenital myopathy Diseases 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 201000009338 distal myopathy Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000001815 facial effect Effects 0.000 claims 1
- 206010016208 familial periodic paralysis Diseases 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 208000025855 muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 4 Diseases 0.000 claims 1
- 230000036473 myasthenia Effects 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 206010030875 ophthalmoplegia Diseases 0.000 claims 1
- 230000001314 paroxysmal effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 208000001076 sarcopenia Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35784602P | 2002-02-21 | 2002-02-21 | |
| US43464502P | 2002-12-20 | 2002-12-20 | |
| PCT/US2003/005150 WO2003072714A2 (en) | 2002-02-21 | 2003-02-21 | Follistatin domain containing proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009212564A Division JP2009286804A (ja) | 2002-02-21 | 2009-09-14 | フォリスタチン（ｆｏｌｌｉｓｔａｔｉｎ）ドメイン含有タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005531505A JP2005531505A (ja) | 2005-10-20 |
| JP2005531505A5 true JP2005531505A5 (enExample) | 2006-03-23 |
| JP4429728B2 JP4429728B2 (ja) | 2010-03-10 |
Family
ID=27767537
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003571402A Expired - Fee Related JP4429728B2 (ja) | 2002-02-21 | 2003-02-21 | フォリスタチン（ｆｏｌｌｉｓｔａｔｉｎ）ドメイン含有タンパク質 |
| JP2009212564A Pending JP2009286804A (ja) | 2002-02-21 | 2009-09-14 | フォリスタチン（ｆｏｌｌｉｓｔａｔｉｎ）ドメイン含有タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009212564A Pending JP2009286804A (ja) | 2002-02-21 | 2009-09-14 | フォリスタチン（ｆｏｌｌｉｓｔａｔｉｎ）ドメイン含有タンパク質 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US7572763B2 (enExample) |
| EP (1) | EP1572934A4 (enExample) |
| JP (2) | JP4429728B2 (enExample) |
| KR (1) | KR20040096592A (enExample) |
| AU (1) | AU2003216345A1 (enExample) |
| BR (1) | BR0307871A (enExample) |
| CA (1) | CA2476654A1 (enExample) |
| MX (1) | MXPA04008149A (enExample) |
| NO (1) | NO20043564L (enExample) |
| PL (1) | PL374966A1 (enExample) |
| WO (1) | WO2003072714A2 (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200526779A (en) | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| MXPA04008149A (es) | 2002-02-21 | 2005-06-17 | Wyeth Corp | Proteinas que contienen dominios de folistatina. |
| MXPA04008150A (es) | 2002-02-21 | 2005-06-17 | Wyeth Corp | Gasp1: una proteina que contiene dominio de folistatina. |
| US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
| BR0314270A (pt) * | 2002-09-16 | 2005-08-02 | Univ Johns Hopkins | Ativação de miostatina com metaloprotease e processos de modulação da atividade da miostatina |
| US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
| US20040223966A1 (en) * | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| CA2513251C (en) * | 2003-01-14 | 2013-03-19 | Dana-Farber Cancer Institute | Cancer therapy sensitizer |
| US7785587B2 (en) * | 2003-06-02 | 2010-08-31 | Wyeth | Therapeutic methods for muscular or neuromuscular disorders |
| EP1644406B1 (en) * | 2003-07-11 | 2012-08-15 | DeveloGen Aktiengesellschaft | Use of dg153 secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome |
| EP1729793B1 (en) * | 2004-03-02 | 2015-07-22 | Acceleron Pharma Inc. | Alk7 and myostatin inhibitors for muscle wasting disorders |
| US8420603B2 (en) * | 2004-05-14 | 2013-04-16 | Abraxis Bioscience, Llc | SPARC and methods of use thereof |
| AU2006249235B2 (en) | 2004-05-14 | 2010-11-11 | Abraxis Bioscience, Llc | Sparc and methods of use thereof |
| WO2005115439A2 (en) * | 2004-05-27 | 2005-12-08 | Acceleron Pharma Inc. | Cerberus/coco derivatives and uses thereof |
| US9045553B2 (en) | 2004-05-27 | 2015-06-02 | Acceleron Pharma, Inc. | Cerberus/Coco derivatives and uses thereof |
| US20060034831A1 (en) * | 2004-08-12 | 2006-02-16 | Wyeth | Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors |
| US7294484B2 (en) | 2004-08-27 | 2007-11-13 | Wyeth Research Ireland Limited | Production of polypeptides |
| US7300773B2 (en) | 2004-08-27 | 2007-11-27 | Wyeth Research Ireland Limited | Production of TNFR-Ig |
| TWI374935B (en) | 2004-08-27 | 2012-10-21 | Pfizer Ireland Pharmaceuticals | Production of α-abeta |
| NZ538097A (en) * | 2005-02-07 | 2006-07-28 | Ovita Ltd | Method and compositions for improving wound healing |
| BRPI0609449A2 (pt) * | 2005-03-23 | 2010-04-06 | Wyeth Corp | detecção de agentes de modulação de gdf-8 |
| JP2008537777A (ja) * | 2005-03-23 | 2008-09-25 | ワイス | Ｇｄｆ−８調節剤に対する免疫応答の検出 |
| PT2407486T (pt) | 2005-08-19 | 2018-02-21 | Univ Pennsylvania | Anticorpos antagonistas contra gdf-8 e utilizações no tratamento de ela e outros distúrbios associados a gdf-8 |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| US7790161B2 (en) * | 2006-03-28 | 2010-09-07 | Wyeth Llc | GDF-9/BMP-15 modulators for the treatment of bone disorders |
| WO2008073351A2 (en) | 2006-12-08 | 2008-06-19 | Acceleron Pharma Inc. | Uses of cerberus, coco and derivatives thereof |
| US8895016B2 (en) * | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| TWI782836B (zh) | 2007-02-02 | 2022-11-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
| PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| US20100008918A1 (en) | 2008-06-26 | 2010-01-14 | Acceleron Pharma Inc. | Methods for dosing an actriib antagonist and monitoring of treated patients |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| JP2013535981A (ja) | 2010-08-20 | 2013-09-19 | ワイス・エルエルシー | 成長因子不含適合細胞の細胞培養 |
| KR20170021919A (ko) | 2011-10-21 | 2017-02-28 | 화이자 인코포레이티드 | 철을 첨가하여 세포 배양을 개선하는 방법 |
| US20180193306A1 (en) | 2012-03-23 | 2018-07-12 | Cardero Therapeutics, Inc. | Compounds and compositions for the treatment of muscular disorders and bone disorders |
| WO2013186719A1 (en) | 2012-06-15 | 2013-12-19 | Pfizer Inc. | Improved antagonist antibodies against gdf-8 and uses therefor |
| ES2791778T3 (es) | 2012-08-01 | 2020-11-05 | Ikaika Therapeutics Llc | Mitigación del daño tisular y la fibrosis a través de anticuerpos anti-LTBP4 |
| CN104981250A (zh) | 2012-10-24 | 2015-10-14 | 细胞基因公司 | 用于治疗贫血的方法 |
| CN104968801B (zh) * | 2012-10-24 | 2021-06-15 | 细胞基因公司 | 用于治疗贫血症的生物标志物 |
| MX366336B (es) | 2012-11-02 | 2019-07-05 | Celgene Corp | Antagonistas de activina - actrii y usos para el tratar trastornos oseos y otros. |
| JP6475639B2 (ja) | 2013-01-25 | 2019-02-27 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | デュシェンヌ筋ジストロフィーの治療におけるフォリスタチン |
| JP2014151438A (ja) * | 2013-02-04 | 2014-08-25 | Koito Mfg Co Ltd | レーザー溶着方法 |
| GB201308117D0 (en) * | 2013-05-06 | 2013-06-12 | Univ Leuven Kath | Inhibitor of calcifying disorders |
| US10010498B2 (en) | 2014-06-04 | 2018-07-03 | Acceleron Pharma Inc. | Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins |
| WO2015187977A1 (en) | 2014-06-04 | 2015-12-10 | Acceleron Pharma, Inc. | Methods and compositions for treatment of disorders with follistatin polypeptides |
| WO2016154601A1 (en) | 2015-03-26 | 2016-09-29 | Acceleron Pharma Inc. | Follistatin-related fusion proteins and uses thereof |
| MX2019001043A (es) | 2016-07-27 | 2019-09-26 | Acceleron Pharma Inc | Metodos y composiciones para el tratamiento de la mielofibrosis. |
| WO2018218273A1 (en) * | 2017-05-29 | 2018-12-06 | Paranta Biosciences Limited | Method of treating hypertension and kidney disease |
| KR101822633B1 (ko) * | 2017-08-22 | 2018-01-26 | (주)진셀팜 | 폴리스타틴 유래 생리활성 펩타이드, 및 이의 용도 |
| CN111989098A (zh) * | 2018-02-20 | 2020-11-24 | 埃皮里姆生物股份有限公司 | 用于治疗肌肉疾病的化合物和组合物 |
| KR20210117271A (ko) | 2018-12-21 | 2021-09-28 | 노쓰웨스턴유니버시티 | 근막 손상 예방 및 치료를 위한 아넥신의 사용근각 손상 예방 및 치료를 위한 아넥신의 사용 |
| WO2020139977A1 (en) | 2018-12-26 | 2020-07-02 | Northwestern University | Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder |
| MX2019015589A (es) * | 2019-12-19 | 2021-06-21 | Centro De Investig Y Asistencia En Tecnologia Y Diseno Del Estado De Jalisco A C | Molécula sintética de adn con potenciador autorregulado por hipoxia y/o inflamación para uso como agente terapéutico de enfermedades inflamatorias y degeneración tisular. |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| EP0272253A4 (en) | 1986-03-07 | 1990-02-05 | Massachusetts Inst Technology | METHOD FOR IMPROVING GLYCOPROTE INSTABILITY. |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5116944A (en) | 1989-12-29 | 1992-05-26 | Neorx Corporation | Conjugates having improved characteristics for in vivo administration |
| US6162896A (en) | 1991-05-10 | 2000-12-19 | The Salk Institute For Biological Studies | Recombinant vertebrate activin receptors |
| EP0590058B1 (en) * | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US20030074680A1 (en) * | 1993-03-19 | 2003-04-17 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
| US6465239B1 (en) * | 1993-03-19 | 2002-10-15 | The John Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species |
| US6673534B1 (en) * | 1995-10-26 | 2004-01-06 | The Johns Hopkins University School Of Medicine | Methods for detection of mutations in myostatin variants |
| US6607884B1 (en) * | 1993-03-19 | 2003-08-19 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-8 |
| US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
| CA2157577C (en) | 1993-03-19 | 2009-11-17 | Se-Jin Lee | Growth differentiation factor-8 |
| US7393682B1 (en) * | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
| PT698094E (pt) | 1993-05-12 | 2004-05-31 | Inst Genetics Llc | Composicoes de bmp-11 |
| DK0716610T3 (da) | 1993-08-26 | 2006-09-04 | Genetics Inst Llc | Humane knogle-morfogenetiske proteiner til anvendelse ved neural regenerering |
| US7332575B2 (en) * | 1994-03-18 | 2008-02-19 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species |
| CA2194660C (en) | 1994-07-08 | 2009-09-29 | Se-Jin Lee | Growth differentiation factor-11 |
| US6008434A (en) | 1994-07-08 | 1999-12-28 | Johns Hopkins University School Of Medicine | Growth differentiation factor-11 transgenic mice |
| US5723125A (en) | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
| WO1998033887A1 (en) | 1997-02-05 | 1998-08-06 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
| US6548644B1 (en) * | 1997-03-10 | 2003-04-15 | Immunex Corporation | Site protected protein modification |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| US6696260B1 (en) | 1997-08-01 | 2004-02-24 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (GDF) binding proteins |
| US6891082B2 (en) * | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| EP1015468A4 (en) * | 1997-08-29 | 2000-09-06 | Human Genome Sciences Inc | FOLLISTATINE-3 |
| AU1276399A (en) | 1997-11-07 | 1999-05-31 | Genetics Institute Inc. | Neuronal uses of bmp-11 |
| US5942420A (en) | 1997-11-17 | 1999-08-24 | Millennium Biotherapeutics, Inc. | Molecules of the follistatin-related protein family and uses therefor |
| US6369201B1 (en) | 1998-02-19 | 2002-04-09 | Metamorphix International, Inc. | Myostatin multimers |
| US6004937A (en) | 1998-03-09 | 1999-12-21 | Genetics Institute, Inc. | Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11] |
| DE69941116D1 (de) | 1998-05-06 | 2009-08-27 | Metamorphix Inc | G von gdf-8 |
| WO2000011163A1 (en) | 1998-08-20 | 2000-03-02 | Regeneron Pharmaceuticals, Inc. | Dcr5, a bmp-binding protein, and applications thereof |
| AU6289999A (en) * | 1998-10-15 | 2000-05-01 | Zymogenetics Inc. | Follistatin-related protein zfsta2 |
| BR0008188A (pt) | 1999-01-21 | 2002-02-13 | Metamorphix Inc | Inibidores de fator de diferenciação de crescimento e usos para os mesmos |
| AU6098300A (en) | 1999-07-16 | 2001-02-05 | Human Genome Sciences, Inc. | Follistatin-3 |
| US7098372B1 (en) * | 1999-09-13 | 2006-08-29 | Wyeth | Pharmaceutical compositions and methods of using secreted frizzled related protein |
| CA2389956A1 (en) * | 1999-11-03 | 2001-02-10 | Zymogenetics, Inc. | Follistatin-related protein zfsta4 |
| WO2001064888A2 (en) | 2000-02-29 | 2001-09-07 | Zymogenetics, Inc. | Kunitz domain polypeptide zkun8 |
| EP1261712B1 (en) * | 2000-03-03 | 2006-12-13 | Curagen Corporation | Proteins named fctrx and nucleic acids encoding same |
| CA2405550A1 (en) * | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US7037501B2 (en) * | 2001-01-04 | 2006-05-02 | Regents Of The University Of Minnesota | Myostatin immnoconjugate |
| TW200526779A (en) | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| MXPA04008150A (es) | 2002-02-21 | 2005-06-17 | Wyeth Corp | Gasp1: una proteina que contiene dominio de folistatina. |
| MXPA04008149A (es) | 2002-02-21 | 2005-06-17 | Wyeth Corp | Proteinas que contienen dominios de folistatina. |
| BR0314270A (pt) | 2002-09-16 | 2005-08-02 | Univ Johns Hopkins | Ativação de miostatina com metaloprotease e processos de modulação da atividade da miostatina |
| US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
| US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| EP2272864A3 (en) | 2002-12-20 | 2011-02-16 | Amgen Inc. | Binding agents which inhibit myostatin |
| BRPI0609449A2 (pt) * | 2005-03-23 | 2010-04-06 | Wyeth Corp | detecção de agentes de modulação de gdf-8 |
| JP2008537777A (ja) * | 2005-03-23 | 2008-09-25 | ワイス | Ｇｄｆ−８調節剤に対する免疫応答の検出 |
-
2003
- 2003-02-21 MX MXPA04008149A patent/MXPA04008149A/es active IP Right Grant
- 2003-02-21 EP EP03743174A patent/EP1572934A4/en not_active Withdrawn
- 2003-02-21 KR KR10-2004-7012978A patent/KR20040096592A/ko not_active Withdrawn
- 2003-02-21 AU AU2003216345A patent/AU2003216345A1/en not_active Withdrawn
- 2003-02-21 US US10/369,738 patent/US7572763B2/en not_active Expired - Fee Related
- 2003-02-21 WO PCT/US2003/005150 patent/WO2003072714A2/en not_active Ceased
- 2003-02-21 CA CA002476654A patent/CA2476654A1/en not_active Abandoned
- 2003-02-21 JP JP2003571402A patent/JP4429728B2/ja not_active Expired - Fee Related
- 2003-02-21 BR BR0307871-0A patent/BR0307871A/pt not_active IP Right Cessation
- 2003-02-21 PL PL03374966A patent/PL374966A1/xx not_active Application Discontinuation
-
2004
- 2004-08-26 NO NO20043564A patent/NO20043564L/no not_active Application Discontinuation
-
2009
- 2009-06-02 US US12/476,489 patent/US20100047259A1/en not_active Abandoned
- 2009-09-14 JP JP2009212564A patent/JP2009286804A/ja active Pending
-
2010
- 2010-09-17 US US12/884,371 patent/US20110020372A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005531505A5 (enExample) | ||
| JP2009286804A5 (enExample) | ||
| EP1140148B1 (en) | Shelf-stable solution formulation of glucagon-like peptide-1 | |
| DK2621515T3 (en) | Chimeric seal-human leptin polypeptide with increased solubility | |
| CN103533951B (zh) | 使用生长分化因子15(gdf‑15)治疗或改善代谢障碍的方法 | |
| ES2238277T3 (es) | Terapia anti-vih con una combinacion de un interferon alfa-pegilado y un antagonista de ccr5. | |
| JP2010512399A (ja) | 医薬製剤及びその調製方法 | |
| JP6755175B2 (ja) | インスリン投薬レジメン | |
| CN118420744A (zh) | 胰岛素衍生物 | |
| JP2011051991A (ja) | サイトカイン、ケモカイン、増殖因子、ポリペプチドホルモン、およびレセプター結合活性が保存されたそのアンタゴニストのポリマー結合体 | |
| TW201733613A (zh) | 用於治療肥胖之升糖素及glp-1共促效劑 | |
| JP2011513212A (ja) | 毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療 | |
| WO2008056726A1 (en) | Glp-1 derivative and use thereof | |
| JP2005530732A5 (enExample) | ||
| US20220152154A1 (en) | Growth differentiation factor 15 combination therapy | |
| BR112021005419A2 (pt) | conjugado que compreende um ou mais polímeros hidrofílicos, uso do mesmo e composição farmacêutica | |
| JPWO2006057152A1 (ja) | タンパク質分解酵素阻害化合物からなる糖尿病治療剤 | |
| JP2007509079A (ja) | 消耗症に罹患している患者の治療における成長ホルモン放出因子類似体の使用 | |
| JPH0242026A (ja) | 関節炎の処置 | |
| JP4564652B2 (ja) | ０．５ｍｌ未満の容量を投与するための凍結乾燥タンパク質組成物を含む１回量注射器 | |
| MXPA05003243A (es) | Terapias para polineuropatia desmielinizante inflamatoria cronica usando interferon-beta. | |
| EP1600162A1 (en) | Shelf-stable formulation of glucagon-like peptide-1 | |
| JPWO2019207505A5 (enExample) | ||
| KR20230004569A (ko) | 항비만 펩티드 및 이의 용도 | |
| US20230293640A1 (en) | Compounds for the treatment of endotheliitis in context of virally caused diseases |